Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.
Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.
复制标题
DOI:
10.3390/vaccines5030027
复制
发表时间:
2017-09-19
期刊:
影响因子:
7.8
通讯作者:
Hegele RG
中科院分区:
文献类型:
--
作者:
Mastrangelo P;Norris MJ;Duan W;Barrett EG;Moraes TJ;Hegele RG
Nucleolin (NCL) has been reported as a cellular receptor for the human respiratory syncytial virus (RSV). We studied the effects of re-purposing AS1411, an anti-cancer compound that binds cell surface NCL, as a possible novel strategy for RSV therapy in vitro and in vivo. AS1411 was administered to RSV-infected cultures of non-polarized (HEp-2) and polarized (MDCK) epithelial cells and to virus-infected mice and cotton rats. Results of in vitro experiments showed that AS1411, used in micromolar concentrations, was associated with decreases in the number of virus-positive cells. Intranasal administration of AS1411 (50 mg/kg) to RSV-infected mice and cotton rats was associated with partial reductions in lung viral titers, decreased virus-associated airway inflammation, and decreased IL-4/IFN-γ ratios when compared to untreated, infected animals. In conclusion, our findings indicate that therapeutic use of AS1411 has modest effects on RSV replication and host response. While the results underscore the challenges of targeting cell surface NCL as a potential novel strategy for RSV therapy, they also highlight the potential of cell surface NCL as a therapeutic target.
登录
查看更多内容
DOI:
10.1165/rcmb.2002-0115oc
发表时间:
2003-06-01
影响因子:
6.4
作者:
Kaan, PM;Hegele, RG
通讯作者:
Hegele, RG
影响因子:
5.8
作者:
Heylen, Elisabeth;Neyts, Johan;Jochmans, Dirk
通讯作者:
Jochmans, Dirk
DOI:
10.1073/pnas.2434327100
发表时间:
2003-12-09
影响因子:
11.1
作者:
Brock, SC;Goldenring, JR;Crowe, JE
通讯作者:
Crowe, JE
影响因子:
2.7
作者:
Adams, Michael J.;Lefkowitz, Elliot J.;Davison, Andrew J.
通讯作者:
Davison, Andrew J.
影响因子:
7.6
作者:
Lee SM;Yen HL
通讯作者:
Yen HL